 |
The Division of Drug Information (DDI)- serving the public by providing information on human drug products and drug product regulation by FDA.
Today the FDA issued two final guidances on compounding using bulk substances:
- Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry (PDF - 127KB)
- Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act (PDF - 106KB)
The agency also posted a statement and a webpage related to these two guidances:
- FDA issues final guidances on interim policy for certain bulk drug substances used in compounding
- Safety Risks Associated with Certain Bulk Drug Substances Nominated for Use in Compounding; Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act
For more information on pharmacy compounding, go to FDA’s Information on Compounding
No hay comentarios:
Publicar un comentario